[ad_1] The US Meals and Drug Administration (USFDA) has granted last permission to Zydus Lifesciences Limited's (beforehand Cadila Healthcare Restricted) U.S. subsidiary Zydus Prescribed drugs (USA) Inc. to commercialise Brivaracetam Tablets USP 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg.Zydus was one of many first ANDA candidates to submit a considerably full ANDA for Brivaracetam Tablets USP 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg with a paragraph IV certification.Brivaracetam Tablets are subsequently eligible for 180 days of shared generic treatment exclusivity.Brivaracetam is permitted for the therapy of partial-onset seizures in kids aged 4 and above.The medication could be produced on the group's formulation manufacturing plant in Ahmedabad Particular Financial Zone, India.In keeping with IQVIA statistics, Brivaracetam Tablets had annual gross sales of USD 412 million in the US (IQVIA MAT August 2022). At round 9.18 AM, Zydus Lifesciences was buying and selling at Rs422.80 up by 0.67% from its earlier closing of Rs420 on the BSE. [ad_2] Source link
